Abstract 476P
Background
Androgen receptor (AR) is a steroid receptor gene located on X chromosome at Xq11–12 and is overexpressed in several solid tumors representing a potential therapeutic target. AR activity and expression is mediated by several genes located on the X chromosome such as: FLNA, UXT and the MAGE family genes (MAGEA1, MAGEA2, MAGEA3, MAGEA9, MAGEA11, MAGEC1, MAGEC2). In this study we investigated the role of AR expression and regulation in patients with gliomas.
Methods
Adult patients with pathologically confirmed grade 2 or 3 or 4 adult-type diffuse gliomas (according to the WHO 2021 classification) treated in our Institution have been evaluated. The AR expression and regulatory status was investigated by Immunohistochemistry (ICH) and gene methylation analysis.
Results
Overall, samples from 50 adult patients have been evaluated. 26 patients were males and 24 were females, with a median age of 51.9 years (range 26.3-76.9). The AR expression detected by ICH was predominant in males (p=0.04), in glioblastoma (GBM) patients IDH-wild type (compared to lower grade adult-type diffuse gliomas, p=0.04), and in astrocytoma (compared to oligodendrogliomas IDH-mutant and 1p19q codeleted, p=0.02). There was an association between AR expression and MGMT methylation, being AR expression more frequently detected in MGMT unmethylated gliomas (p=0.02). AR was found hypomethylated in cases with immunohistochemical positivity AR (Kruskal Wallis < 0.05). UXT, MAGEA1, and MAGEA1-11 were hypermethylated in AR-positive gliomas (Kruskal Wallis < 0.05). AR hypomethylation was deeper in GBM (Kruskal Wallis <0.05).
Conclusions
AR expression is higher in MGMT unmethylated tumors, astrocytoma, glioblastoma IDH-WT, and male patients. The methylation of AR regulatory genes on the X chromosome mediates AR expression. These data indicate that the AR pathway could be important in adult-type diffuse gliomas suggesting a potential role of antiandrogen therapies in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Istituto delle Scienze Neurologiche di Bologna.
Funding
CARISBO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16